Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q2- Text added to 2020 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
begun, bond, CStone, divestiture, EC, fitelparvovec, Giroctocogene, guided, handling, Hexal, Hierarchy, Hong, JPO, Kong, Macau, mainland, missed, neoadjuvant, outlicensed, pace, PfizerCommercial, phosphate, prodrug, purpura, readout, recovering, rulemaking, sasanlimab, Sawai, Secretary, slower, storage, sugemalimab, Taiwan, temperature, thrombocytopenic, tightened, unapproved, unlock, weighted, win, women
Removed:
Acknowledgment, andNew, AstraZeneca, Austrian, bear, borrow, divided, duly, embedded, enactment, Extension, file, ICU, immunosuppression, improvement, Inline, instance, interactive, lymphoproliferative, matching, mind, predominantly, prevailing, rebating, region, registrant, reinvestment, Schema, served, smoothened, strive, table, Taxonomy, thereunto, undersigned, weakening, XBRL
Valuein 2020 Q2 filing- Value in 2020 Q3 filing
Original filings
Filing view